Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lyra Therapeutics (LYRA) EPS (Basic) (2021 - 2025)

Lyra Therapeutics (LYRA) has disclosed EPS (Basic) for 5 consecutive years, with -$9.21 as the latest value for Q3 2025.

  • On a quarterly basis, EPS (Basic) fell 1.54% to -$9.21 in Q3 2025 year-over-year; TTM through Sep 2025 was $29.9, a 164.44% increase, with the full-year FY2024 number at -$1.43, down 13.49% from a year prior.
  • EPS (Basic) was -$9.21 for Q3 2025 at Lyra Therapeutics, down from -$5.51 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $44.75 in Q4 2024 to a low of -$36.76 in Q2 2024.
  • A 5-year average of -$1.21 and a median of -$0.44 in 2023 define the central range for EPS (Basic).
  • Biggest YoY gain for EPS (Basic) was 20440.91% in 2024; the steepest drop was 10111.11% in 2024.
  • Lyra Therapeutics' EPS (Basic) stood at -$1.05 in 2021, then skyrocketed by 65.71% to -$0.36 in 2022, then surged by 38.89% to -$0.22 in 2023, then surged by 20440.91% to $44.75 in 2024, then crashed by 120.58% to -$9.21 in 2025.
  • Per Business Quant, the three most recent readings for LYRA's EPS (Basic) are -$9.21 (Q3 2025), -$5.51 (Q2 2025), and -$0.13 (Q1 2025).